ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

House Committee Adopts Drug Bills

by Britt E. Erickson
May 20, 2013 | APPEARED IN VOLUME 91, ISSUE 20

The House of Representatives’ Energy & Commerce Committee on May 15 approved measures that would secure the U.S. pharmaceutical supply chain and reauthorize FDA to collect fees from manufacturers of animal drugs. One bill, H.R. 1919, would create a national standard for securing the drug supply chain to replace recently enacted laws in a number of states. It would also require FDA to propose an electronic system for tracking drugs throughout the supply chain by 2027. Several Democrats on the committee opposed the bill, saying a tracking system is needed now, not in 14 years. A second bill, H.R. 1407, would reauthorize the Animal Drug User Fee Act and the Animal Generic Drug User Fee Act, both of which expire on Sept. 30. The measure would allow FDA to collect more than $30 million in fees from the animal drug industry to support the review of New Drug Applications for brand-name and generic animal drugs. The bill would not require FDA to track the sale and use of antibiotics in animals, despite heavy pressure from consumer groups for such a provision.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment